Cronos Group (CRON) vs Eton Pharmaceuticals (ETON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Cronos Group (CRON) over the past year, gaining 159.5% versus a gain of 23.7%. Over five years, ETON leads with a +953.4% price change compared with -40.9% for CRON. Eton Pharmaceuticals is the larger company by market cap ($1.57 billion vs $1.17 billion), about 1.3 times the size.
On valuation, Cronos Group trades at a lower trailing P/E (16.8x vs 137.3x for Eton Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRON | ETON |
|---|---|---|
| Share price | $3.19 | $54.94 |
| Market cap | $1.17B | $1.57B |
| 1-day change | -1.70% | +0.11% |
| YTD return | +23.19% | +224.54% |
| 1-year return | +23.66% | +159.48% |
| 5-year return | -40.88% | +953.36% |
| P/E ratio (TTM) | 16.76 | 137.35 |
| Forward P/E | — | 21.29 |
| EPS (TTM) | $0.19 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.61 | $66.37 |
| 52-week low | $2.28 | $14.27 |
| Distance from 52-week high | -11.72% | -17.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | -22.76% | +29.23% |
| Average volume | 1.13M | 606.07K |
| Shares outstanding | 368.41M | 28.58M |
| Employees | 610 | 44 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed CRON by 135.8 percentage points over the past year.
- Eton Pharmaceuticals trades at a higher earnings multiple (137.3x vs 16.8x trailing P/E).
About Cronos Group
CRON stock →Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Health Care · Medicinal Chemicals and Botanical Products · 610 employees
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
CRON vs ETON FAQ
Which is bigger, Cronos Group or Eton Pharmaceuticals?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.57B compared with $1.17B for Cronos Group (CRON).
Which stock has performed better over the past year, CRON or ETON?
ETON returned +159.48% over the past 12 months, compared with +23.66% for CRON (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CRON or ETON?
CRON has the lower trailing P/E at 16.8, versus 137.3 for ETON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Cronos Group and Eton Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Cronos Group and Biotechnology: Pharmaceutical Preparations for Eton Pharmaceuticals.